Conference Call to be held August 19, 2019, at 4:30pm Eastern Time MINNEAPOLIS , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the
MINNEAPOLIS , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), today announced its Skyline Medical division has received its first order from India for four machines to be sold to local hospitals.
Three Most Recent Pittsburgh-Based Development Partnerships Demonstrate Value and Recognition for Helomics’ AI-Driven, Patient Derived “Multi-Omic” Discovery Platform MINNEAPOLIS , July 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a
PITTSBURGH , July 18, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products
MINNEAPOLIS, Minn ., June 26, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement
MINNEAPOLIS , June 12, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has appointed Amelia Warner , Pharm.D., RPh, as the
Nasdaq ticker expected to change to POAI Effective Thursday, June 13, 2019 MINNEAPOLIS , June 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery,
MINNEAPOLIS , May 21, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. , (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that its Helomics division has been selected as the
MINNEAPOLIS , May 17, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that Nasdaq has determined that the Company is eligible for a
Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 4:30PM Today MINNEAPOLIS , May 15, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized